NeuroScientific Biopharmaceuticals Limited
NeuroScientific Biopharmaceuticals Limited (NSB.AX) Stock Overview
Explore NeuroScientific Biopharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
23.1M
P/E Ratio
19.82
EPS (TTM)
$0.01
ROE
0.23%
NSB.AX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of NeuroScientific Biopharmaceuticals Limited (NSB.AX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 71.61, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $0.02.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 19.82 and a market capitalization of 23.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
Anthony James Keating
85 Forrest Street, Cottesloe, WA
2018